Species-specific activity of antibacterial drug combinations

Nature

Volumn 559, Issue 7713, 2018, Pages 259-263

  Brochado, Ana Rita ^a   Telzerow, Anja ^a   Bobonis, Jacob ^a   Banzhaf, Manuel ^a,j   Mateus, André ^a   Selkrig, Joel ^a   Huth, Emily ^b   Bassler, Stefan ^a   Zamarreño Beas, Jordi ^c   Zietek, Matylda ^a   Ng, Natalie ^d   Foerster, Sunniva ^e   Ezraty, Benjamin ^c   Py, Béatrice ^c   Barras, Frédéric ^c,f   Savitski, Mikhail M ^a   Bork, Peer ^a,g,h,i   Göttig, Stephan ^b   Typas, Athanasios ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d Stanford University   (United States)

^e UNIVERSITY OF BERN   (Switzerland)

^f INSTITUT PASTEUR   (France)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^h Molecular Medicine Partnership Unit   (Germany)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; GENTAMICIN; SPECTINOMYCIN; VANILLIN; ANTIINFECTIVE AGENT; BENZALDEHYDE DERIVATIVE; FOOD ADDITIVE;

ADDITIVE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL DISEASE; BACTERIUM; DRUG RESISTANCE; MICROBIAL ACTIVITY; PATHOGEN; PHYLOGENETICS; PUBLIC HEALTH; RELATEDNESS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL DENSITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GALLERIA MELLONELLA; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LARVAL STAGE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR PHYLOGENY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SURVIVAL; ANIMAL; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; GRAM NEGATIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; LARVA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; MULTIDRUG RESISTANCE; PHYLOGENY; SPECIES DIFFERENCE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; GALLERIA MELLONELLA; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;

ANIMALS; ANTI-BACTERIAL AGENTS; BENZALDEHYDES; COLISTIN; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ESCHERICHIA COLI; FOOD ADDITIVES; GRAM-NEGATIVE BACTERIA; LARVA; MICROBIAL SENSITIVITY TESTS; MOTHS; PHYLOGENY; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; SPECIES SPECIFICITY;

EID: 85049778232     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-018-0278-9     Document Type: Article

References (52)

1. President of the General Assembly of the United Nations. Press release: high-level meeting on antimicrobial resistance (http://www.un.org/pga/71/2016/09/21/press-release-hl-meeting-on-antimicrobial-resistance/) (2016).
2. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature 529, 336-343 (2016).
3. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318-327 (2018).
4. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011).
5. Brown, D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat. Rev. Drug Discov. 14, 821-832 (2015).
6. Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A. & Collins, J. J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130, 797-810 (2007).
7. Ezraty, B. et al. Fe-S cluster biosynthesis controls uptake of aminoglycosides in a ROS-less death pathway. Science 340, 1583-1587 (2013).
8. Yeh, P., Tschumi, A. I. & Kishony, R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38, 489-494 (2006).
9. Robbins, N. et al. An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens. Cell Reports 13, 1481-1492 (2015).
10. Cokol, M. et al. Large-scale identification and analysis of suppressive drug interactions. Chem. Biol. 21, 541-551 (2014).
11. Bollenbach, T., Quan, S., Chait, R. & Kishony, R. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139, 707-718 (2009).
12. Costanzo, M. et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 353, aaf1420 (2016).
13. Farha, M. A. & Brown, E. D. Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity. Chem. Biol. 17, 852-862 (2010).
14. Stokes, J. M. et al. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. Nat. Microbiol. 2, 17028 (2017).
15. Chevereau, G. & Bollenbach, T. Systematic discovery of drug interaction mechanisms. Mol. Syst. Biol. 11, 807 (2015).
16. Ryan, C. J. et al. Hierarchical modularity and the evolution of genetic interactomes across species. Mol. Cell 46, 691-704 (2012).
17. Vaara, M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in Gram-negative enteric bacteria. Antimicrob. Agents Chemother. 37, 354-356 (1993).
18. Giamarellou, H., Zissis, N. P., Tagari, G. & Bouzos, J. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 25, 534-536 (1984).
19. Imamura, Y. et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. 49, 1377-1380 (2005).
20. Petropoulos, A. D. et al. Time-resolved binding of azithromycin to Escherichia coli ribosomes. J. Mol. Biol. 385, 1179-1192 (2009).
21. Hao, Z. et al. The multiple antibiotic resistance regulator MarR is a copper sensor in Escherichia coli. Nat. Chem. Biol. 10, 21-28 (2014).
22. Chubiz, L. M., Glekas, G. D. & Rao, C. V. Transcriptional cross talk within the mar-sox-rob regulon in Escherichia coli is limited to the rob and marRAB operons. J. Bacteriol. 194, 4867-4875 (2012).
23. Göttig, S., Hamprecht, A. G., Christ, S., Kempf, V. A. & Wichelhaus, T. A. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity. J. Antimicrob. Chemother. 68, 1737-1740 (2013).
24. Göttig, S., Gruber, T. M., Stecher, B., Wichelhaus, T. A. & Kempf, V. A. In vivo horizontal gene transfer of the carbapenemase OXA-48 during a nosocomial outbreak. Clin. Infect. Dis. 60, 1808-1815 (2015).
25. MacNair, C. R. et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat. Commun. 9, 458 (2018).
26. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).
27. Yardeni, E. H., Zomot, E. & Bibi, E. The fascinating but mysterious mechanistic aspects of multidrug transport by MdfA from Escherichia coli. Res. Microbiol. https://doi.org/10.1016/j.resmic.2017.09.004 (2017).
28. Bohn, C. & Bouloc, P. The Escherichia coli cmlA gene encodes the multidrug efflux pump Cmr/MdfA and is responsible for isopropyl-β-d-thiogalactopyranoside exclusion and spectinomycin sensitivity. J. Bacteriol. 180, 6072-6075 (1998).
29. Nichols, R. J. et al. Phenotypic landscape of a bacterial cell. Cell 144, 143-156 (2011).
30. Wildenhain, J. et al. Prediction of synergism from chemical-genetic interactions by machine learning. Cell Syst. 1, 383-395 (2015).
31. Chandrasekaran, S. et al. Chemogenomics and orthology-based design of antibiotic combination therapies. Mol. Syst. Biol. 12, 872 (2016).
32. Lehár, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659-666 (2009).
33. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97, 6640-6645 (2000).
34. Saka, K. et al. A complete set of Escherichia coli open reading frames in mobile plasmids facilitating genetic studies. DNA Res. 12, 63-68 (2005).
35. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
36. Yeh, P. J., Hegreness, M. J., Aiden, A. P. & Kishony, R. Drug interactions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7, 460-466 (2009).
37. Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615 (1939).
38. Loewe, S. Die quantitativen Probleme der Pharmakologie. Ergeb. Physiol. 27, 47-187 (1928).
39. Szappanos, B. et al. An integrated approach to characterize genetic interaction networks in yeast metabolism. Nat. Genet. 43, 656-662 (2011).
40. Mateus, A. et al. Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Proc. Natl Acad. Sci. USA 114, E6231-E6239 (2017).
41. Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299-304 (2017).
42. Piddock, L. J., Jin, Y. F., Ricci, V. & Asuquo, A. E. Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 43, 61-70 (1999).
43. t method. Methods 25, 402-408 (2001).
44. Kritikos, G. et al. A tool named Iris for versatile high-throughput phenotyping in microorganisms. Nat. Microbiol. 2, 17014 (2017).
45. Safdar, N., Handelsman, J. & Maki, D. G. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4, 519-527 (2004).
46. Taber, H. W., Mueller, J. P., Miller, P. F. & Arrow, A. S. Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev. 51, 439-457 (1987).
47. Mazzariol, A., Tokue, Y., Kanegawa, T. M., Cornaglia, G. & Nikaido, H. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob. Agents Chemother. 44, 3441-3443 (2000).
48. Davis, B. D., Chen, L. L. & Tai, P. C. Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides. Proc. Natl Acad. Sci. USA 83, 6164-6168 (1986).
49. Miller, P. F., Gambino, L. F., Sulavik, M. C. & Gracheck, S. J. Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli. Antimicrob. Agents Chemother. 38, 1773-1779 (1994).
50. Fernandes, F., Neves, P., Gameiro, P., Loura, L. M. & Prieto, M. Ciprofloxacin interactions with bacterial protein OmpF: modelling of FRET from a multi-tryptophan protein trimer. Biochim. Biophys. Acta 1768, 2822-2830 (2007).
51. Machado, D. et al. Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant Mycobacterium tuberculosis. PLoS ONE 11, e0149326 (2016).
52. Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623-628 (2018).